Tarsus joins Stargardt race to market with $800m Alkeus takeover

Summary

Tarsus has acquired Alkeus for $800 million to compete in the Stargardt disease market, which currently has no approved treatments. Multiple companies including Belite Bio, Ocugen, and Nanoscope are also pursuing therapeutic options for this indication.